NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Lite Strategy, Inc. (LITS) Stock Analysis

Lite Strategy, Inc. (LITS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LITS

$1.24

+$0.05 (+4.20%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LITS with… →

LITS Key Statistics

As of Oct 21, 2026
Trading
Open
$1.21
Previous Close
$1.19
Day's Range
1.20–1.27
52-Week Range
0.69–2.26
Volume
154.42K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.01
Valuation
Market Cap
$37.71M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.22
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.06
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$15.95M−189.69%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
30.41M
1-Year Return
−36.41%
Dividend and dates
Earnings Date
November 13, 2026estimated
Avg Volume
476.89K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LITS closed at $1.24, −36.41% over 1 year.

Lite Strategy, Inc. (LITS) has a market capitalization of $37.71M.

In fiscal 2025, LITS reported revenue of $0.00.

LITS Stock Return by Calendar Year

Lite Strategy, Inc. (LITS) 10-year return: what $10,000 became

1 year
$10,000 $6,359
−36.41%
5 years
$10,000 $291
−97.09%
10 years
$10,000 $493
−95.07%

If you had invested $10,000 in Lite Strategy, Inc. (LITS) 10 years ago, at the close on October 21, 2016, it would have been worth $493 at the close on October 21, 2026: −95.07% in total, −26.00% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−6.06%
2025−46.34%
2024−57.59%
2023+55.55%
2022−91.01%
2021+1.14%
2020+6.45%
2019−6.06%
2018+25.71%
2017+45.83%
2016 (partial year)−30.10%

As of October 21, 2026.

LITS Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$15.95M—
2024$65.30M$17.78M27.2%
2023$48.82M−$31.84M−65.2%
2022$40.70M−$54.45M−133.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$17.46M−$15.95M—
2024$65.30M—$25.44M$17.78M27.2%
2023$48.82M—−$36.76M−$31.84M−65.2%
2022$40.70M$40.70M−$75.48M−$54.45M−133.8%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lite Strategy, Inc. (LITS) carries a market capitalisation of $37.71M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 5.

Over the past 52 weeks the price has ranged from $0.69 to $2.26. The most recent close on file for LITS is $1.24, dated October 21, 2026. That is +$0.05 (+4.20%) against the previous close. The latest close sits 79.71% above that 52-week low.

Financial Health

In fiscal 2025, Lite Strategy, Inc. reported revenue of $0.00. Against the prior fiscal year total of $65.30M, that is a change of −100.00%. The same year closed with a net loss of $15.95M. Earnings per share on a trailing basis come to −2.06.

Across the 4 fiscal years on file, revenue moves from $40.70M in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.22.

The reported beta is 0.01. Annualized volatility over the trailing 10 years is 77.18%. Over the trailing twelve months the total return is −36.41%. Measured over 10 years, that is −26.00% a year compounded.

Growth & Income

The dividend record for LITS runs through 2023.

So far in 2026 the total return is −6.06%. Across the complete calendar years on file, 2023 returned +55.55% and 2022 returned −91.01%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Lite Strategy, Inc. (LITS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lite Strategy, Inc. LITS $37.71M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Lite Strategy, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Lite Strategy, Inc.

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Visit website →